Vor Biopharma Inc (VOR) Price

Vor Biopharma Stock Soars On Telitacicept Data

Vor Biopharma's stock surged over 45% after the company announced positive Phase 3 results for its drug, telitacicept. The rally was further fueled by JPMorgan initiating coverage with a favorable outlook, citing the drug's de-risked profile.